Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrea Obi

Vascular Surgery Ann Arbor, MI Medical Doctor

NPI 1851554570 CMS profile 1042724

1500 East Medical Center, Ann Arbor, MI 48109

Open in the dashboard

General payments

$7,797

32 records reported · program years 2021–2025

Research payments

$3,975

Paid to them · 5 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$396,285 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Andrea Obi of Ann Arbor, MI is reported in the CMS Open Payments database as having received $7,797 across 32 general payments and $3,975 in research payments paid to them. Separately, studies naming them as principal investigator received $396,285 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $57 2
2024 General $645 3
2023 General $42 1
2023 Research $600 2
2022 General $6,042 16
2022 Research $125 1
2021 General $1,011 10
2021 Research $3,250 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrea Obi
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Andrea Obi were reported at $57. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Andrea Obi Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $1,011 $471 $158–$1,421 $132
2022 $6,042 $725 $222–$2,183 $149
2023 $42 $836 $257–$2,440 $160
2024 $645 $909 $252–$2,619 $164
2025 $57 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $7,339 26 payments
  2. Boston Scientific Corporation $368 3 payments
  3. Surmodics, Inc. $90 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $5,525 3 payments
  2. Travel and Lodging $1,159 6 payments
  3. Food and Beverage $1,114 23 payments
Products named General payments · program years 2021–2025
  1. VENASEAL $4,800 1 payment
  2. Abre $1,179 15 payments
  3. General - Thrombectomy $148 1 payment
  4. EKOSONIC $138 1 payment
  5. Pounce Venous Thrombectomy System $90 3 payments
  6. VENOUS WALLSTENT $82 1 payment
  7. Sublime 014 Rx PTA Balloon Dilatation Catheter $46 2 payments
  8. Sublime Microcatheter, 018, 200cm, Straight $46 2 payments
  9. Pounce Thrombectomy System $46 2 payments
  10. Pounce Thrombectomy $46 2 payments
  11. Other $9 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Medtronic, Inc. $3,975 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

32

Median for Vascular Surgery: 122

Drug cost

$12,680

Median for Vascular Surgery: $14,135

Branded share of claims

50%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 16 $12,010
Warfarin Sodium Generic 16 $670

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$32,102

Medicare's payments for the services billed

Medicare patients

860

Average age 70

Services billed

1,089

435 women, 425 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 49%
Chronic kidney disease 49%
Diabetes 46%
Heart failure 41%
Atrial fibrillation 34%
Depression 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record